Mouse model of anti-RANKL discontinuation reveals reduced bone mass and quality through disruption of bone remodeling

Abstract The discontinuation of denosumab [antibody targeting receptor activator of nuclear factor kappa B ligand (RANKL)] therapy may increase the risk of multiple vertebral fractures; however, the underlying pathophysiology is largely unknown. In patients who underwent discontinuation after multip...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Koji Ishikawa, Soji Tani, Nobuhiro Sakai, Yoshifumi Kudo, Hideyo Horiuchi, Hiromi Kimura-Suda, Masamichi Takami, Mayumi Tsuji, Katsunori Inagaki, Yuji Kiuchi, Takako Negishi-Koga
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2025-05-01
Seri Bilgileri:Bone Research
Online Erişim:https://doi.org/10.1038/s41413-025-00433-0
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller